Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

Treatment for stage 3 myeloma is typically divided into phases. The goal is to achieve a deep remission, meaning the cancer ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for relapsed patients. This year brought major advances across the multiple ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...

Many of these advances are the result of decades of work and clinical trials. Since the mid-1990s, the American Cancer ...

Data shows iberdomide combination therapy delivers progression free survival and safety in relapsed and refractory multiple ...

Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for ...

Immunotherapy is a type of cancer treatment that uses the power of a person’s immune system to fight their cancer. Instead of directly attacking cancer cells like chemotherapy or radiation, ...

Radiation therapy is a treatment that uses high doses of radiation to damage cancer cells, either killing them or slowing their growth. Unlike the low-dose radiation used in X-rays to see inside the ...

aps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma ...